Abstract | Brain metastases are a serious obstacle in the treatment of patients with solid tumors and contribute to the morbidity and mortality of these cancers. It is speculated that the frequency of brain metastasis is increasing for several reasons, including improved systemic therapy and survival, and detection of metastases in asymptomatic patients. The lack of preclinical models that recapitulate the clinical setting and the exclusion of patients with brain metastases from most clinical trials have slowed progress. Molecular factors contributing to brain metastases are being elucidated, such as genes involved in cell adhesion, extravasation, metabolism, and cellular signaling. Furthermore, the role of the unique brain microenvironment is beginning to be explored. Although the presence and function of the blood-brain barrier in metastatic tumors is still poorly understood, it is likely that some tumor cells are protected from therapeutics by the blood-tumor barrier, creating a sanctuary site. This Review discusses what is known about the biology of brain metastases, what preclinical models are available to study the disease, and which novel therapeutic strategies are being studied in patients.
Introduction
Metastatic brain tumors are the most frequently occurring intracranial neoplasms in adults with the annual incidence in the USA estimated to be 200,000 cases. 1 Furthermore, an estimated 8-10% of adults with cancer develop sympto matic brain metastases. 2, 3 The majority of brain metastases originate from primary cancers in the lung (40-50%) or breast (15-25%), or from melanoma (5-20%). 2, 3 The frequency of diagnosis of metastatic brain tumors seems to be increasing as a result of improved imaging modalities and earlier detection as well as longer survival after primary cancer diagnosis because of more-effective treatment of systemic disease.
The distribution of brain metastases correlates with blood flow and tissue volume, with 80% detected in the cerebral hemispheres, 15% in the cerebellum, and 5% in the brainstem. 4 The majority of patients exhibit multiple tumors at the time of brain-metastasis diagnosis. Clinical features include headache, neurological deficit, and seizures. Neuropsychological testing demonstrates cognitive impairment in 65% of patients with brain metastases, 5, 6 which might be a result of destruction or displacement of brain tissue by the expanding tumor, peritumoral edema leading to further disruption of surrounding white matter tracts, increased intracranial pressure, and/or vascular compromise.
Therapeutic approaches for brain metastases include surgery, whole-brain radiation therapy (WBRT), stereotactic radiosurgery (SRS), chemotherapy, growth factor inhibitors, or a combination of these therapies. Survival for patients with brain metastases treated with WBRT typically ranges from 4-6 months, but can be as long as 12-24 months for selected patients. 6 Strong positive prognostic factors include good functional status, age <65 years, no sites of metastasis outside of the central nervous system (CNS), controlled primary tumor, 7 the presence of a single metastasis in the brain, long interval from primary diagnosis to brain relapse, and certain cancer subtypes such as HER2-positive breast cancer and EGFR-mutant non-small-cell lung cancer (NSCLC). [8] [9] [10] In up to half of patients the cause of death is attributed to CNS progression. 11 Randomized clinical trials have shown that surgery or SRS combined with WBRT improves overall survival compared with WBRT alone in patients with a single metastasis in the brain. In patients with four or fewer brain metastases, SRS results in equivalent overall survival but worse intracranial disease control compared with SRS plus WBRT. [11] [12] [13] [14] [15] The combination of radio therapy and chemo therapy improves response rate and/or progression-free survival in some studies, but not overall survival.
extravasate, survive and proliferate within a secondary site (Figure 1 ), is an inherently inefficient process. 19 Certain tumor types demonstrate an organ-specific pattern of spread; for example, prostate cancer frequently metastasizes to bone and melanoma frequently meta stasizes to the lung, liver and brain. 20, 21 Stephen Paget was the first to hypothesize that the propensity of cancer cells to spread to specific sites was dependent upon two factors: the cancer cell (the 'seed') and the receiving organ environment (the 'soil'). 22 An alternative hypo thesis attributed to pathologist James Ewing proposes that circu latory patterns between the primary tumor and specific second ary organs are sufficient to explain the majority of organspecific metastatic spread. 23 A newer hypo thesis is that cancer cells can bring their own soil-stromal components from the primary site including activated fibroblasts-to secondary sites. 24 Researchers have sought to understand how molecular and genetic features of the primary cancer cell, the brain micro environment, and the angiogenic pathways influence spread of cancer to the brain and its growth there (Table 1 ).
Brain microenvironment
Once metastatic cancer cells enter the brain circulation, they might arrest in sites of slow flow within the capillary bed at vascular branch points, 25 which is then followed by early changes in the brain microenvironment. 26 The arrested cancer cells encounter brain vascular endothelial cells, which seem to promote metastatic tumor cell growth and invasion. 25, 27 In addition, stromal cells such as fibroblasts associated with the primary tumor are involved in metastatic nodules in the brain (Figure 1 ). 24 These co-disseminating stromal cells provide survival and prolifera tive advantages to the tumor cells and facilitate early colonization of metastatic foci. The brain also provides an environment that differs from most other organs, and the factors that either promote or suppress colonization and proliferation are poorly understood (Table 1) . Thus, successful treatment of CNS metastases may require targeting of both tumor and host responses.
Response of host stromal cells
After infiltration into the brain tissue, cancer cells encounter a number of host cell types, including microglia and astrocytes. Microglia displaying stellate morphology with thick cellular processes, characteristic of an activated state, have been observed around extra vastated cancer cells within 7 days of intracarotid injection of breast cancer cell lines into mice. 26 Activated astrocytes with thick processes and upregulated expression of glial fibrillary acidic protein can be seen even earlier, when cancer cells are still in the intravascular space, and they remain closely associated with cancer cells throughout their growth into macrometastases. 26 In a xenograft model, reactive astrocytes and microglia were in direct contact with tumor cells along the border of the tumors as well as infiltrating the inner tumor mass. Similar findings were reported in human specimens. In addition, in vitro co-cultures demonstrated that glia induced a fivefold increase in metastatic cell proliferation, leading the researchers to hypothesize that reactive glia creates an altered brain microenvironment that is more permissive to tumor growth and invasion. 28 Consistent with these findings, expression of endo thelin 1, a regulator of numerous transforming processes, was observed in peritumoral astrocytes in 85% of hematogeneous metastases of the human brain. 29 Furthermore, additional studies suggest that microglia can enhance the invasion and coloni zation in the brain tissue by breast cancer cells similar to other tissue-specific stromal cells such as osteoblasts and osteoclasts in the bone. 30, 31 Most likely, during the early stages of brain metastasis formation, there is a balance between the protective or trophic, and cytotoxic functions of microglia, dependent on the release of a variety of factors and ultimately determined by signals from tumor cells. 32 Protective roles of astrocytes Astrocytes within the brain microenvironment might serve to protect brain metastases from cytotoxicity induced by chemotherapeutic drugs. 33 In co-culture experiments, the presence of astrocytes but not fibroblasts dramatically reduced 5-fluorouracil-induced and cisplatin-induced apoptosis in human tumor cells. 34 The protective effect was lost when cells were separated with a trans-well membrane, suggesting that direct contact of astrocytes with tumor cells, rather than secreted factors, was mediating the chemoprotective effect. Similar effects have also been demonstrated in human melanoma cell lines, 35 breast cancer cells, and lung cancer cells.
36
Soluble factors also have an important role in tumor cell-astrocyte interaction. Activated astrocytes surround brain metastatic lesions from lung cancer, both in an experimental mouse model and in the human brain. 78 Also, activation of integrins, such as α v β 3 54,139 and β 1 , 27 is suggested to control tumor-cell arrest and adhesion to the vasculature. c | Metastasizing tumor cells (seeds) may bring their own host cells (soil) in metastasis. 24 After extravasation, tumor cells either d | grow along pre-existing blood vessels (perivascular growth), 49 or e | recruit new blood vessels (angiogenesis) to obtain sufficient nutrients to support their proliferation. Abbreviation: BBB, blood-brain barrier.
Angiogenesis
The growth and proliferation of primary and metastatic tumors is dependent on the establishment of an adequate blood supply. [40] [41] [42] A tumor can recruit blood vessels via different mechanisms: angiogenesis (sprouting from existing blood vessels), vasculogenesis (formation of a de novo vascular system from endothelial precursor cells), co-option (growth of cancer cells along existing blood vessels), intussusception (vessel remodeling and expansion by the insertion of interstitial tissue columns into the lumen of pre-existing vessels), vasculogenic mimicry (cancer cells lining blood vessels), cancer cells that transdifferentiate into endothelial cells, 43 and cancer stem-like cells that form an inner lining of blood vessels in the brain. [44] [45] [46] [47] Changes in brain vasculature Kienast et al. 25 used multiphoton laser scanning microscopy and a mouse cranial window model to follow in real time brain metastasis formation from both lung cancer and melanoma cell lines. After extravasation, there was a persistent correlation between tumor cells with microvessels and either vessel co-option (with melanoma) or angiogenesis (with lung carcinoma). Previous studies showed a similar association between meta stasizing tumor cells and blood vessels. 27, 28, 48, 49 Kusters et al. 48 showed that a melanoma brain metastasis could grow up to 3 mm through co-opting pre-existing blood vessels. Similar observations in murine experimental brain metastases models from breast cancer and melanoma cells indicate that an active adhesion mechanism exists between tumor cells and the vascular basement membrane. 27 Metastatic brain tumor vessels in preclinical models and human surgical specimens have significantly larger diameters and thicker basement membranes when compared with the vessels of normal brain. 50 Brain meta stases from murine melanoma, murine fibrosarcoma, human lung carcinoma, and human colon carcinoma have a lower microvascular density than the surrounding normal brain parenchyma, and they all contain dilated blood vessels with large lumens. 50 The mechanism for this enlargement seems to involve endothelial cell proliferation.
Angiogenic factors in brain metastasis
The progressive growth of the majority of metastatic brain tumors is critically dependent on the expression of VEGF. 51 In a brain metastatic variant of MDA-MB-231 cells, there was a significant increase in VEGF-A production, and inhibition of VEGFR activity significantly reduced brain tumor burden after intracarotid injection in mice. 52 Moreover, when human lung cancer cells transfected with antisense VEGF165 were injected into the carotid artery of nude mice, the formation of brain metastases was substantially decreased compared with untransfected cells. 51 However, in cells transfected with VEGF121 or VEGF165, no increase in metastasis was observed, indicating that VEGF expression is necessary but not sufficient for the production of brain metastases. In another study, VEGFR inhibition with cediranib did not impede tumor cell extravasation in a murine model of brain metastasis from a prostate cancer primary. 53 These data suggest hetero geneity between different tumor cells and types.
Activation of integrin α v β 3 on tumor cells strongly promotes metastatic breast tumor growth in the brain by enabling tumor cells to attract blood vessels independent of hypoxia, an effect mediated by post-transcriptional control of VEGF expression. 54 Other growth factors including angiopoietin 1 and 2, bFGF, PlGF, SDF1α, PDGF and IL-8 have been implicated in the angiogenesis pathway in primary tumors and gliomas, but their role remains to be established in metastatic brain tumors. 43 ,55 
Hostile microenvironment impairs drug delivery
In cancer, the balance between proangiogenic and antiangiogenic factors tips towards angiogenesis owing to the overexpression of proangiogenic growth factors. This overexpression leads to blood vessels that are structurally and functionally abnormal, exhibiting heterogeneous and often sluggish blood flow and hyperpermeability. 50, [56] [57] [58] [59] A heterogeneous and inefficient blood vessel network creates regions of hypoperfusion or no perfusion where reduced nutrients and oxygen, and impaired waste removal, creates an abnormal metabolic environment, characterized by hypoxia and acidosis. Furthermore, vascular hyperpermeability induces tumor interstitial hypertension, which hinders drug penetration owing to the lack of convective transport. 60, 61 Clearly, host-tumor interactions including angio genesis have an important role in the formation and expansion of brain metastases. However, the knowledge of the molecular mechanisms required during the formation of metastatic lesions is still lacking. What is certain is that the molecular and cellular changes within metastatic brain tumor vasculature and the micro environment should be considered when designing strategies to improve the delivery and efficacy of therapeutic agents.
Modeling and imaging brain metastases
Substantial progress has been made over the past two decades in modeling human cancer in the mouse and, more recently, model systems have emerged that recapitulate many aspects of metastatic disease to the CNS. An important barrier to the development of reliable CNS mouse models is that in most orthotopically transplanted primary tumors that give rise to metastatic foci, the animals succumb to systemic disease before the brain can be reliably studied. Therefore, current models often rely on either direct implantation of tumors into the brain or iterative selection of brain-seeking clones resulting from experimental hematogeneous dissemination to the brain to enrich metastatic disease in the CNS. These experimental metastasis models inevitably miss the initial steps of the metastatic cascade and thus may not reflect the full clinical manifestation of the disease.
Animal models of brain metastasis
Various preclinical animal models for the study of brain metastases and their advantages and limitations are summarized in Table 2 . Rodent model systems for brain metastasis have been reported for multiple cancer types, including melanoma, 62, 63 lung carcinoma, 64 and breast carcinoma. [65] [66] [67] [68] [69] [70] [71] The emergence of new animal models of brain metastasis that more closely mimic human disease provides the tools necessary to understand all of the steps involved in the process. Unfortunately, the field is still limited by the few spontaneous models available and the complexity of more clinically relevant models.
Melanoma
Melanoma mouse models have been established using a variety of murine and human melanoma cell lines injected via an intracardiac, intracarotid or, less successfully, 70 established a brain-seeking clone (MDA-MB-231BR) of the human breast cancer cell line MDA-MB-231 by serial in vivo and in vitro passages. In a mouse xenograft, when the MDA-MB-231BR cell line was transfected with HER2, the HER2-overexpressing clones demonstrated a threefold increase in the number of large brain metastases compared with untransfected MDA-MB-231BR cells; however, the number of micrometastases was unaffected. 73 This model has also been used to probe the effect of anti-HER2 therapies on the development and propagation of brain metastases. 74 Alternatively, human breast cancer cells implanted near the surface of the brain provide a model to directly observe tumor and vessel growth using a cranial window and intravital microscopy (Figure 2a-c) . 75, 76 Spontaneous metastasis Few reports describe cell lines capable of reproducibly spontaneously metastasizing to the CNS from a primary tumor. These include a variant of the murine B16 melanoma cell line (named G3.5), generated through successive rounds of selection of brain metastases following intravenous injection, which leads to spontaneous metastasis to the CNS from subcutaneous primary tumors in 80% of mice. 77 Using a similar method, a brain metastatic variant of the triple-negative breast cancer cell line CN34 (CN34-BrM2) capable of metastasizing to the CNS from a primary mammary tumor in about 42% of mice was generated. 78 A procedure that might more accurately replicate the selection mechanisms of clinical brain meta stasis formation was established from long-term, low-dose metro nomic chemotherapy treatment of mice injected subdermally with a highly metastatic variant of the WM239A human melanoma cell line. 63 Among long-term surviving mice, 20% had spontaneous brain metastases, and cell lines generated from these metastases spontaneously metastasized to the brain parenchyma after ortho topic transplantation and removal of the primary tumor. 63 
Preclinical imaging techniques
Visualization and quantification of metastatic disease burden in the brain is an indispensible component of any metastasis model system. Several novel methods of in vivo imaging have been developed that allow for serial measurements over time before animal sacrifice, including window models (Figure 2a-c,f,g ). For instance, the MDA-MB-231 human breast cancer cell line has been engineered to express a naturally secreted Gaussia luciferase (Gluc) and in an orthotopic primary and brain metastatic mouse model, quantitative serum and urine Gluc levels correlated well with overall tumor burden. 76 Importantly, Gluc activity in the blood revealed early growth of metastatic brain tumors before they could be detected by bioluminescence imaging (Figure 2e) . An alternative adaptation of quantitative fluorescent and phosphorescent imaging techniques has recently been developed that interrogates blood-tumor barrier (BTB) permeability within and surrounding metastatic brain tumors in mice, using tumor cells expressing enhanced green fluorescent protein (eGFP) and Texas red dextran as a marker of passive permeability. 79 This model also allows simultaneous quantification of BTB permeability using radiolabeled chemotherapeutic drugs. Combining these techniques with the MDA-MB-231BR HER2-overexpressing mouse model previously described, 70 Lockman et al. 79 analyzed over 2,000 brain metastases and demonstrated that BTB permeability was compromised in over 89% of lesions. 79 However, 14 C-paclitaxel and 14 C-doxorubicin only reached cytotoxic concentrations in about 10% of metastases. 79 Other powerful imaging technologies include MRI, PET and near-infrared optical imaging. 80, 81 In the past, the majority of MRI studies of brain tumors in mice were performed using high-field-strength MRI (≥7 Tesla) because of its high spatial resolution and signal-to-noise ratio (Figure 2d) . 82, 83 However, several techniques enhance the sensitivity of clinical-strength MRI scanners (1.5-3 Tesla) for the detection of small brain metastases in rodents. When MDA-BR-231-eGFP cells are labeled with fluorescent μm-sized superparamagnetic iron oxide (MPIO) particles, single labeled breast cancer cells can be detected in the rat brain parenchyma as small dark or hypointense voxels on T2*-weighted MRI that then develop into metastases after 4 weeks. 84 The same cells labeled with ferumoxides-protamine sulfate (FEPro) could be detected and quantified within 2 weeks of intracardiac injection using T2*-weighted 3-Tesla MRI with better sensitivity than bioluminescence imaging, providing a powerful tool for both spatial and temporal monitoring of metastatic tumor growth and progression. 85, 86 Novel therapeutic strategies
The role of chemotherapy in the treatment of brain metastasis has been limited owing to multiple factors: poor blood-brain barrier (BBB) penetrability of many systemically active chemotherapeutic drugs; the tendency for many patients to have had multiple rounds of chemotherapy prior the development of CNS metastatic disease; and the historical exclusion of patients with brain metastases from clinical trials testing new agents. New therapies and strategies are increasingly being explored that aim to enhance drug delivery to the brain, complement the effects of radiation therapy, substitute the role of radiation therapy, or act as preventative agents against the development of new metastases. Furthermore, with the development of new models and imaging techniques (Figure 2h,i) , preclinical treatment strategies can become more focused on established brain metastases, necessary for translational potential.
Crossing the blood-brain barrier The BBB is a selective barrier between the systemic circulation and cerebrospinal fluid that is formed by specialized endothelial cells lining the cerebral microvasculature, together with pericytes and astrocytic perivascular endfeet (Figure 3) . 87 Tight junctions between adjacent cells force most molecules to pass through, rather than around, endothelial cells, creating a physical barrier. Transport systems on the luminal and abluminal membranes regulate the passage of small hydrophilic molecules. Large hydrophilic molecules, including many chemotherapeutic and molecular-targeted drugs, are excluded from the CNS unless they can be actively transported by receptor-mediated transcytosis. In addition, the BBB expresses high levels of drug efflux pumps such as the P-glycoprotein (PgP)/multi-drug resistance proteins, 88 which actively remove some chemotherapeutic drugs from the brain.
When metastatic tumors grow beyond 1-2 mm in diameter within the brain parenchyma, the BBB becomes structurally and functionally compromised. 56, 58, 75, [89] [90] [91] [92] In an experimental brain metastasis model of eight human tumor lines, lesions smaller than 0.2 mm 2 contained an intact BBB; however, larger tumor-cell clusters resulted in leakage of sodium fluorescein indicating that the function of the BBB is directly related to the size of the lesion, and a growing tumor mass may disrupt the interaction of astrocytes and endothelial cells. 93 In addition to changes in blood vessel permeability, there was a significant reduction in PgP expression to 5% and 40% of normal levels in brain metastases from melanoma and lung carcinoma, respectively. 94 The disruption of the BBB might not be homogeneous, and the BBB might remain intact at least in parts of tumors. Thus, barriers to drug delivery to such lesions might still need to be overcome.
It is widely thought that macroscopic metastatic brain tumors have a disrupted BBB, as evidenced by homogeneous contrast enhancement on MRI. Brain metastases, distinct from infiltrative gliomas, have sharp borders and can usually be completely resected if their location allows. However, not all single metastases are amenable to surgical resection, and even those tumors that are assumed to be totally resected at the time of surgery have a recurrence rate of up to 50% when postoperative radiation therapy is not employed. 95 In addition, there are likely micrometastatic deposits in many patients at the time of diagnosis that are not well visualized by MRI, have an intact BBB, and contribute to CNS recurrence after initial local therapy, and some macroscopic tumors have a relatively intact BBB. 79 Therefore, strategies to circumvent the challenges of an intact BBB are likely to be needed in some patients for improved intracranial disease control (Table 3 ). An alternative approach to physical and local disruption techniques is to design drugs that can be shuttled across the BBB using receptors that are naturally expressed on the endothelial cells of the BBB (Figure 3) . Preclinical studies have demonstrated feasibility using anti bodies against transferrin and insulin receptors, as well as peptides targeting the receptor lipoprotein receptor-related protein (LRP-1).
96-98 LRP-1 is highly expressed at the BBB, is involved in the transport of proteins and peptides such as β-amyloid, tissue plasminogen activator, melano transferrin and receptor-associated peptide, and is upregulated in brain tumors. 96, 97, [99] [100] [101] GRN1005 (Angiochem, Montreal, QC, Canada), is paclitaxel linked to angiopep2 (a ligand for LRP-1) and is in phase I clinical trials in patients with metastatic brain tumors or malignant gliomas.
102,103 GRN1005 has antitumor acti vity in sub cutaneously implanted glioblastoma and lung tumors and extends the survival of mice with intra cerebral tumors. 104 In addition, in the MDA-MB-231BR mouse model, there was a fourfold to 54-fold increase in in vivo uptake of GRN1005 into brain and brain meta stases compared with paclitaxel. 105 Another mechanism to increase the concentration of anticancer agent in the CNS is to inhibit their efflux by targeting the efflux transporters that comprise the BBB (Figure 3a-c) .
Sensitizing tumor cells to radiation
Although WBRT leads to stabilization or shrinkage of tumors in at least half of patients, many patients have tumor recurrence either at sites of original disease or in new sites, some of which may have been present at the time of initial treatment but below the threshold of detection. There is, therefore, continued interest in developing drugs that act to sensitize tumor cells to radiation therapy, with the goal of improving local and distant control rates over radiation alone while sparing toxicity to normal tissue. Multiple agents with preclinical radiosensitizing properties have failed to show benefit in randomized controlled trials, including lonidamine, metronidazole, misonidazole, motexafin gadolinium, bromodeoxyuridine, and efiproxiral. 6, [106] [107] [108] [109] [110] [111] Several chemo therapeutic agents with preclinical evidence of both radiosensitizing properties and BBB penetration have been tested in trials in combination with WBRT, including temozolomide and topotecan, but none has emerged as clearly superior to WBRT alone. 16, 18, 112 The histone deacetylase inhibitor vorinostat has shown promise as a radiosensitizer in multiple cells lines as well as in brain using the MDA-MB-231BR mouse model, where an improvement in both tumor growth delay and overall survival was seen compared with radiation alone. 113 In a separate study using the MDA-MB-231BR mouse model, vorinostat as a single agent reduced the size and number of brain metastases formed compared with vehicle-treated controls, raising the possibility that this agent might be useful as a prophylactic agent in patients who are at high-risk of tumor relapse in the brain. 114 The mechanism of the prevention of metastasis by vorinostat seems to be the induction of DNA doublestrand breaks associated with the downregulation of the DNA repair gene RAD52, indicating that vorinostat sensitizes the tumor to DNA-targeting therapies such as radiation. 114 Vorinostat in combination with WBRT is being tested in a phase I clinical trial in patients with brain metastases from multiple solid tumor types and in a phase I trial in combination with SRS in patients with brain metastases from NSCLC.
115,116
Targeting angiogenesis There are conflicting preclinical data as to whether inhibition of angiogenesis results in tumor growth delay and a reduction in metastatic potential, or promotes altered growth patterns via vessel co-option and increased metastatic potential. 48, 49, 52 There are limited clinical data to support the phenomenon of vessel co-option and infiltrative growth of metastatic brain tumors under the influence of antiangiogenic therapy, 46 but angiogenesis inhibitors have not been systematically studied in brain metastases mainly owing to concerns about the potential for intracranial hemorrhage. Such concerns have been substantially allayed with the publication of reviews of large clinical trial datasets and two prospective clinical trials. These studies show that the risk of CNS hemorrhage in patients with solid tumors that have not spread to the CNS, as well as in patients with stable brain meta stases at the time of initiation of antiangiogenic therapy, is low (0.8-3.3%) and not above rates that would be expected independent of anti angiogenic agent exposure. [117] [118] [119] [120] Therefore, clinical trials have been launched to determine the safety and efficacy of various anti angiogenic agents in combination with either radiation therapy or single-agent chemotherapy for the treatment of new or progressive brain metastases from solid tumors. 121 Other targeted therapies NSCLC Brain metastases from NSCLC have been shown to respond to the EGFR inhibitors gefitinib and erlotinib. In patients with unselected NSCLC brain metastasis, there was a response rate of 10-38% to gefitinib (complete and partial), with a median duration of response of 9-13.5 months. 122, 123 Similar findings have been documented with erlotinib. [124] [125] [126] As for extracranial disease, response is highly dependent on the presence of an activating EGFR mutation. 122, 123 Patients who were treatment naive were particularly responsive: in 23 Asian neversmokers with brain metastases from a NSCLC primary treated with first-line erlotinib or gefitinib, a 70% CNS response rate was observed, 127 and all seven patients with brain metastases enrolled on a phase II study of erlotinib for chemotherapy-naive advanced-stage NSCLC achieved an objective CNS response. 128 Retrospective data indicate that patients with brain metastases from EGFR-mutant NSCLC might have improved overall survival compared with EGFR wild-type cancers, particularly when they receive treatment with an EGFR inhibitor. 10 As new genetic subpopulations of NSCLC are identified that can be targeted with small-molecule inhibitors, such as cancers harboring an ALK rearrangement that are responsive to crizotinib, 129 it will be important to assess whether there is a differential response to targeted therapies in the CNS compared with extracranial sites of disease. The CNS responses seen with the first generation of small-molecule EGFR inhibitors in properly selected patients suggest that the use of drugs that are highly effective is at least as important as drug delivery for treating patients with brain metastases. [159] [160] [161] Inhibiting the drug efflux pump (for example, HM30181A, cyclosporine A, valspodar, elacridir, zosuquidar)
Administration concurrently with chemotherapy for broad applications Abbreviations: BBB, blood-brain barrier; IGF-1R, insulin-like growth factor-1 receptor; IR, insulin receptor; LRP-1, low density lipoprotein receptor-related protein 1; PgP, P-glycoprotein; RMT, receptor-mediated transcytosis; TfR, transferrin receptor.
HER2-amplified breast cancer
Patients with HER2-positive breast tumors are at high risk of developing brain metastases, with a frequency as high as 35% in patients with advanced-stage disease. 130, 131 A combination of factors likely explains the increased incidence of CNS disease in these patients, including the ability of HER2 to increase brain colonization 73 via its downstream molecules including heparanase-a target of microRNA-1258 132 -and improved control of systemic disease with the anti-HER2 monoclonal antibody, trastuzumab, which has poor BBB penetration. 130 Lapatinib, a small-molecule tyrosine kinase inhibitor of EGFR and HER2, has limited acti vity as a single agent for patients with refractory brain metastases, 133 but slightly higher activity in combination with capecitabine. 134 In a phase III randomized study of capecitabine plus lapatinib versus capecitabine alone for advanced-stage, trastuzumabrefractory breast cancer, fewer patients in the combination arm had sympto matic CNS progression as part of the first progression event compared with those not receiving lapatinib. 135 Furthermore, in a preclinical study using an experimental model of HER2-positive breast cancer brain meta stases, lapatinib inhibited the formation of large brain metastases by 54%, suggesting preventative activity and supporting the clinical findings. 74 It should be noted that trastuzumab not only directly affects HER2-expressing tumor cells but also acts as an antiangiogenic cocktail by downregulating multiple proangiogenic factors and inducing endo genous antiangiogenic factors, and normalizes blood vessels of breast cancer grown in the leptomeningeal space. 75 Unfortunately, the decrease in VEGF expression in cancer cells is compensated by an increase in VEGF expression in host cells. These findings suggest that an anti-VEGF agent (for example bevacizumab) might be beneficial when combined with trastuzumab or lapatinib. 75 Ongoing clinical trials of combined anti-VEGF and anti-HER2 therapies in patients with metastatic breast cancer will likely shed on whether this hypothesis is supported by the data.
136
Melanoma Melanoma accounts for 5-20% of all brain metastases, and 40-60% of melanomas carry an activating mutation in the gene encoding BRAF, a serine-threonine protein kinase. 137 In a phase I study, administration of an inhibitor of mutated BRAF, PLX4032 (Plexxikon, Berkeley, CA, USA), to patients with metastatic melanoma harboring this mutation resulted in complete or partial tumor regression in the majority of patients. However, patients with active brain metastases were excluded from this study. 137 In a separate study using the BRAF inhibitor GSK2118436 (GlaxoSmithKline, Brentford, UK), all seven evaluable patients with previously untreated brain metastases showed CNS tumor shrinkage, including three complete responses, and parallel extracranial responses were noted in most patients. 138 
Conclusions
Many genes whose products are necessary for the steps of brain metastases formation-in particular extravasation and colonization-have been identified. New developments of more clinically relevant models and advanced imaging techniques over the past couple of years have begun to facilitate understanding of the intricacies of brain metastases. It is increasingly evident that the brain microenvironment has a key role in the metastatic growth process, as well as in resistance to antitumor therapies. Delivery of drugs across the BBB is a challenge, albeit more so in smaller lesions. Although the BTB is not as tight as the BBB, concentrations of drugs in brain lesions are usually lower compared with extracranial sites. The grand challenge now is to integrate this knowledge and develop novel strategies to target the unique microenviron ment of brain metastasis.
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